Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN  
496.32
-2.36 (-0.47%)
Products

Regeneron Says FDA Grants Dupixent Breakthrough Therapy Designation For Eosinophilic Esophagitis

Published: 09/14/2020 05:13 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis.
Regeneron - U.S. FDA Granted Breakthrough Therapy Designation to Dupixent for Treatment of Patients 12 Years and Older With Eosinophilic Esophagitis.
Regeneron Pharmaceuticals- Designation for This Investigational Use is Based on Positive Results From Part a of a Phase 3 Trial in Patients With Eoe.
Regeneron- Potential Use of Dupixent in Eosinophilic Esophagitis is Currently Under Clinical Development.
Regeneron- Dupixent in Eosinophilic Esophagitis is Currently Under Clinical Development& Its Safety and Efficacy for This Indication Have Not Been Evaluated by Any Regulatory Authority.